Self-administration of omalizumab: why not? A literature review and expert opinion. (3rd April 2021)
- Record Type:
- Journal Article
- Title:
- Self-administration of omalizumab: why not? A literature review and expert opinion. (3rd April 2021)
- Main Title:
- Self-administration of omalizumab: why not? A literature review and expert opinion
- Authors:
- Menzella, Francesco
Ferrari, Emanuele
Ferrucci, Silvia Mariel
Lombardi, Enrico
Alfano, Silvio
Bonavita, Ornella
Morini, Paolo
Rizzi, Andrea
Matucci, Andrea - Abstract:
- ABSTRACT: Introduction : Omalizumab is used to treat severe uncontrolled allergic asthma and chronic spontaneous urticaria (CSU), and is approved for self-administration in prefilled syringes. It is thus important to understand the advantages, critical issues, and indications for home administration. Areas covered : The present review summarizes the available evidence on home administration of omalizumab in asthma and CSU to illustrate the advantages derived from self-administration of patients in this setting. Expert opinion : The available data suggest that patients can safely administer biologics at home with suitable training, and that home administration is time saving and cost-effective. The majority of patients with severe asthma or CSU treated with omalizumab are likely to be suitable candidates for self-administration, which can be proposed to anyone that the clinician deems suitable. In addition to clinicians, pharmacists can also play a key role in managing patients who are prescribed home administration. A practical flow chart is proposed on selection of patients and their management during home administration. Self-administration of biologics can be considered as a valid alternative to traditional injections in a clinical setting, and the evidence has shown that no major issues need to be overcome in terms of safety or efficacy.
- Is Part Of:
- Expert opinion on biological therapy. Volume 21:Number 4(2021)
- Journal:
- Expert opinion on biological therapy
- Issue:
- Volume 21:Number 4(2021)
- Issue Display:
- Volume 21, Issue 4 (2021)
- Year:
- 2021
- Volume:
- 21
- Issue:
- 4
- Issue Sort Value:
- 2021-0021-0004-0000
- Page Start:
- 499
- Page End:
- 507
- Publication Date:
- 2021-04-03
- Subjects:
- Biologics -- chronic spontaneous urticaria -- home administration -- omalizumab -- self-administration -- severe asthma -- therapy
Gene therapy -- Periodicals
Protein drugs -- Periodicals
Peptide drugs -- Periodicals
Immunotherapy -- Periodicals
Drug delivery systems -- Periodicals
615.5 - Journal URLs:
- http://informahealthcare.com/journal/ebt ↗
http://www.ashley-pub.com/loi/ebt ↗
http://www.tandfonline.com/toc/iebt20/current ↗
http://informahealthcare.com ↗
http://miranda.ashley-pub.com/vl=2623054/cl=18/nw=1/rpsv/journal/journal1_home.htm ↗ - DOI:
- 10.1080/14712598.2021.1882990 ↗
- Languages:
- English
- ISSNs:
- 1471-2598
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 3842.002940
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 16359.xml